Shaily Engineering Plastics Ltd (SHAILY) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Shaily Engineering Plastics reported strong revenue growth of 22% to INR787 crores in FY25, driven by a 53% increase in the Healthcare segment.
- EBITDA margins expanded by 350 basis points to 22.7% due to the growth in the higher-margin Healthcare segment.
- The company signed eight contracts for pen injectors and auto-injectors, primarily for GLP-1 therapies.
- Shaily is expanding pen manufacturing capacity by 40-50 million units per year with a capex of INR150 crores to meet growing GLP-1 demand.
- The company is focused on expanding its medical device business, which is expected to contribute ~30% of revenues in the next few years.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.